据创鉴汇不完全统计,6月16日至6月22日全球生物制药领域共披露27起交易事件,潜在交易总额超34亿美元,涉及抗体偶联药物(ADC)、基因编辑、核药、小分子药物等核心领域。上周交易多数为未披露金额的研发合作,但包含4起超亿美元的大额并购、授权合作事件。其中,礼来以约13亿美元收购Verve Therapeutics,双方早在2023年6月就已经针对心血管疾病合作研发基因编辑药物。本次收购将继续强化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.